Treatment in The Early Stages of Psychosis

Essay Concerning Treatment of a “Moving Target”
  • Jan Libiger
Part of the NATO Science Series book series (ASID, volume 91)

Abstract

The paper was originally intended to discuss the treatment of early schizophrenia. However, the mention of first episode schizophrenia was avoided and replaced by “early stages of psychosis”. The reason was that it is better to avoid assuming knowledge that we do not possess. What are the boundaries of the disease concept we call schizophrenia? When does it really begin? In the history of psychiatry, the diagnosis of schizophrenia was given to patients with different psychopathology and different courses of the disorder. Different treatment modalities may be required for treating various aspects of psychopathology. The success in controlling positive symptoms of schizophrenia may lead to deterioration of other, less conspicuous psychopathology, e.g. negative or cognitive symptoms.

Keywords

Schizophrenia Prolactin Haloperidol Clozapine Risperidone 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Altamura, A.C. (1997) Treatment of Schizophrenic Disorders, European Algorithm ProjectPsychiatry in Clinical Practice1, Suppl.1, 25–30.Google Scholar
  2. 2.
    Amsler, H.A., Reerenhovi, L., Bertha, E. et al. (1977) Agranulocytosis in patients treated with clozapine: a study of Finnish epidemicActa Psych. Scand.56, 241–248.CrossRefGoogle Scholar
  3. 3.
    Breier, A., Wolkowitz, O.M., Doran, A.R. et al. (1987) Neuroleptic responsivity of positive and negative symptoms in schizophrenia.Am. J Psychiat.144, 1549–1555.PubMedGoogle Scholar
  4. 4.
    Breier, A., Buchanan, R.W., Kirkpatrick, B. et al. (1994) Effects of clozapine on positive and negative symptoms in outpatients with schizophreniaAm. J Psychiat.151, 20–26.PubMedGoogle Scholar
  5. 5.
    Buchanan, R.W., Breier, A., Kirkpatrick, B., Bal, P. and Carpenmter, W.T. Jr. (1998) Positive and negative symptom response to clozapine in schizophrenic patients with and without the deficit syndromeAm. J Psychiat.155, 751–760.PubMedGoogle Scholar
  6. 6.
    Carman, J., Peuskens, J., and Vangeneugden, A. (1995) Risperidone in the treatment of negative symptoms of schizophrenia: a meta-analysisInt. Clin. Psychopharm.10, 207–213.CrossRefGoogle Scholar
  7. 7.
    Carpenter, W.T., Heinrichs, D.W., and Wagman, A.M. (1988) Deficit and non deficit form of schizophrenia: a conceptAm. J. Psychiat.145, 578–583.PubMedGoogle Scholar
  8. 8.
    Casey, D.E. (1995)Neuroleptic Induced Acute Extrapyramidal Syndromes and T7ardive Dyskinesiain S.R. Hirsch and D.R.Weinberger,SchizophreniaBlackwell Science, Oxford.Google Scholar
  9. 9.
    Cole, J.M., Klerman, G.L. et al.: Phenothiazine treatment of acute schizophreniaArch. Gen. Psychiat.10, 246–261, 1964.CrossRefGoogle Scholar
  10. 10.
    Davis, J.M. and Garver, D.L. (1978)Neuroleptics clinical use in psychiatry in L. Iversen, S.Iversen, et al. (eds.),Handbook of Psychopharmacology Plenum Press, New York.Google Scholar
  11. 11.
    Davis, K.L., Kahn, R.S., Ko, G. et al. (1991) Dopamine in schizophrenia: a review and reconceptualizationAm. J Psychiat.148, 1474–1486.PubMedGoogle Scholar
  12. 12.
    Depue, R.A. and Collins, P.F. (1999) Neurobiology of the Structure of Personality: Dopamine, Facilitation of Incentive Motivation, and Extraversion, accepted for publication inBrain and Behaviour Sciences Google Scholar
  13. 13.
    Farde, L., Nordstrom, A.L., Wiesel, F.A. et al. (1992) Positron emission tomographic analysis of central DI and D2 dopamine receptor in patients treated with classical neurolpetics and clozapine: relation to extrapyramidal side effectsArch. Gen. Psychiat.49, 538–544.PubMedCrossRefGoogle Scholar
  14. 14.
    Fibiger, H.C. (1996) Immediate Early Gene Expression and the Mechanism of Action of Atypical DrugsEuropean Neuropsychopharm.6, Suppl.3, 25.Google Scholar
  15. 15.
    Gerlach, J. (1997) Treatment resistance: Are there specific strategies?Eur. Neuropsychopharm.7, Suppl.2, 107.Google Scholar
  16. 16.
    Goldberg, S.C. (1985) Negative and deficit symptoms in schizophrenia do respond to neurolepticsSchizophrenia Bull.11, 453–456.CrossRefGoogle Scholar
  17. 17.
    Grebb, J. (1996) Will novel antipsychotics be the next standard of care for patients with schizophrenia: A world wide report on risperidoneEuropean Neuropsychopharm.6, Suppl. 3, 17Google Scholar
  18. 18.
    Harvey, P.D., Putnam, K.M., Davidson, M. et al. (1991) Brief neuroleptic discontinuation and clinical symptoms in Kraepelinian and non-Kraepelinian chronic schizophrenic patientsPsychiatry Res.38, 285–292.PubMedCrossRefGoogle Scholar
  19. 19.
    Huttunen, M.(1995) The evolution of serotonin-dopamine antagonistconcept J Clin Psychopharmacol. 15 / Suppl1,4S–10SCrossRefGoogle Scholar
  20. 20.
    Iqbal, N.,van Praag,H. (1995)The role of serotonin in schizophrenia Eur.Neuropsychopharmacol.5/ Suppl.l 1–23Google Scholar
  21. 21.
    Janicak, P.G., Davis, J.M., Preskorn, S.H. and Ayd, F.J. (1993)Principles and Practice of PsychopharmacotherapyWilliams and Wilkins, Baltimore.Google Scholar
  22. 22.
    Janicak, P.G., Javaid, J.1., Sharma, R.P. et al. (1997) A two-phase, double blind randomized study of the haloperidol plasma levels for acute psychosis with reassignment of initial non-respondersActa Psych. Scand.95, 343–350.CrossRefGoogle Scholar
  23. 23.
    Johnson, D.A.W. (1978) Practical considerations in the use of depot neuroleptics for the treatment of schizophreniaBrit. J Hosp. Med.17, 549–559.Google Scholar
  24. 24.
    Kahn, R.S., Davidson, M., Siever, L. et al. (1993) Haloperidol and clozapine treatment and their effect on m-chlorphenylpiperazin-mediated responses in schizophrenia: implications for clozapine’s mechanism of actionPsychopharma‑ col.112, 90–94.CrossRefGoogle Scholar
  25. 25.
    Kane, J.M. (1996) SchizophreniaN. Engl. J. Med.334, 34–41.PubMedCrossRefGoogle Scholar
  26. 26.
    Kane, J., Honigfeld, G., Singer, J. et al. (1988) Clozapine for the treatment resistant schizophrenic: a double blind comparison with chlorpromazineArch. Gen. Psychiat.45, 789­-796.Google Scholar
  27. 27.
    Kaplan, H.I., Sadock,B. J. Grebb,J.A.(1994)Synopsis of psychiatryWilliams and Wilkins, Baltimore,7theditionGoogle Scholar
  28. 28.
    Kapur, S., Remington, G., Jones, C. et al. (1996) High levels of dopamine D-2 receptor occupancy with low dose haloperidol treatment: A PET studyAm. J. Psychiat.153, 948–950.PubMedGoogle Scholar
  29. 29.
    LeMoal, M., Simon, H. (1991) Mesocorticolimbic Dopaminergic Network: Functional and Regulatory RolesPhysiol. Rev.71, 155–234.Google Scholar
  30. 30.
    Leysen, J.E., Janssen, P.M.F., Schotte, A. et al. (1993) Interaction of antipsychotic drugs with neurotransmitter receptor sites in vitro and in vivo in relation to pharmacological and clinical effects: role of 5HT - 2 receptorsPsychopharmaco‑ logy112, 40–54.CrossRefGoogle Scholar
  31. 31.
    Liddle, P.F., Friston, K.J., Frith, C.D. et al. (1992) Patterns of Cerebral Blood Flow in SchizophreniaBrit. J Psychiat.160, 179–186.PubMedCrossRefGoogle Scholar
  32. 32.
    Lindstroem, L.H. (1987) The effect of long term treatment with clozapine: a retrospective study in 96 patients treated with clozapine for up to 13 yearsActa Psych. Scand.77, 524–529.CrossRefGoogle Scholar
  33. 33.
    Marder, S.R. and Meibach, R.C. (1994) Risperidone in the treatment of schizo­phreniaAm. J Psychiat.151, 825–834.PubMedGoogle Scholar
  34. 34.
    May, P.R.A. (1968)Treatment of SchizophreniaScience House, New York.Google Scholar
  35. 35.
    May, P.R.A., Tuma, A.H. and Dixon, W.J. (1976) Schizophrenia: a follow-up study of results of five forms of treatmentArch. Gen. Psychiat.38, 776–783.CrossRefGoogle Scholar
  36. 36.
    McDermott, B.E., Sautter, F.J. and Garver, D.L. (1991) Heterogeneity of Schizophrenia: Relationship to Latency of Neuroleptic ResponsePsych. Res.37, 97–103.CrossRefGoogle Scholar
  37. 37.
    McEvoy, J.P., Weiden, P.J., Smith, T.E. et al. (1996) Treatment of schizophrenia. The expert consensus guideline series, JClin. Psychiat.57, Suppl. 12B.Google Scholar
  38. 38.
    McEvoy, J.P., Hogarty G.E., Steingard, S. (1991) Optimal dose of neuroleptic in acute schizophrenia: a controlled study of neuroleptic threshold and higher haloperidol doseArch. Gen. Psychiat.48, 739–745.PubMedCrossRefGoogle Scholar
  39. 39.
    Meltzer, H.Y., Matsubara, S. and Lee, J.C. (1993) Classification of typical and atypical drugs on the basis of dopamine D1, D2 and serotonin pK;valuesPsychopharm. Bull.25, 390–392.Google Scholar
  40. 40.
    Moeller, H.J., Mueller, H., Borison, R.L. et al. (1995) A path analytical approach to differentiate between direct and indirect drug effects on negative symptoms in schizophrenic patients: a reevaluation of the North American risperidone studyEur. Arch. Psychiat. Clin. Neurosci.245, 45–49.CrossRefGoogle Scholar
  41. 41.
    .Mohr, P. and Czobor, P. (1999a) Subject selection for the placebo and standard controlled trials of neuroleptics in schizophrenia. Accepted for publication inJ Clin.Psychopharm. Google Scholar
  42. 42.
    Mohr, P., Horá ek, J., Motlová, L., Libiger, J. and Czobor, P. (1998) Prolactin response to D­fenfluramine challenge test as a predictor of treatment response to haloperidol in acute schizophreniaSchizophr. Res.30, 91–99.PubMedCrossRefGoogle Scholar
  43. 43.
    Mohr, P., Horá ek, J., Motlová, L., Libiger, J., Czobor, P. (1999b) Effects of haloperidol treatment on prolactin response do D-fenfluramine challenge in acute schizophreniaPsychopharmacology141, 322–325.CrossRefGoogle Scholar
  44. 44.
    Peuskens, J. and the Risperidone study group (1995) Risperidone in the treatment of chronic schizophrenic patients: a multinational, multicenter, double blind, parallel group study versus haloperidolBrit. I Psychiat.166, 712–726.CrossRefGoogle Scholar
  45. 45.
    .Psychotropic Drug Guidelines (1995) 3rded. Victorian Medical Postgraduate Foundation, Melbourne.Google Scholar
  46. 46.
    Rifkin, A., Doddi, S., Karajgi, B. et al. (1991) Dosage of Haloperidol for SchizophreniaArch.Gen. Psychiat.48, 166–171.PubMedCrossRefGoogle Scholar
  47. 47.
    Thau, K. (1998)Diagnosis and course of mood disorders/bipolar disordersPresented at the workshop of International Group for Study of Lithium, Prague.Google Scholar
  48. 48.
    Tien, A.Y. and Gallo, J.J. (1997) Clinical Diagnosis: A Marker for Disease? JNerv. Ment. Disease185, 739–747.CrossRefGoogle Scholar
  49. 49.
    Tollefson, G.D., Sanger, T.M. and Beasley, C.M. (1997) The course of primary and secondary negative symptoms in a controlled trial with olanzapineSchizophr. Res.24, 192.Google Scholar
  50. 50.
    Tuomisto, J., Mannisto P. (1985) Neurotransmitter Regulation of Anterior Pituitary HormonesPharmacol. Rev3, 249–332Google Scholar
  51. 51.
    Vanelle, J.M. (1996) Profile of neuroleptic drugs and therapeutic response in deficit schizophreniaEncephale22/ Spec. issue 2, 33–39Google Scholar
  52. 52.
    Van Kammen, D.P., Hommer, D.W. and Malas, K.L. (1987) Effect of pimoside on positive and negative symptoms in schizophrenic patients, are negative symptoms state dependent?Neuropsychobiology18,113–117.PubMedCrossRefGoogle Scholar
  53. 53.
    Volavka, J., Cooper, T.B. and Czobor, P. (1995) Plasma haloperidol levels and clinical effects in schizophrenia and schizoaffective disorderArch. Gen. Psychiat.52, 837/845.CrossRefGoogle Scholar
  54. 54.
    Wolkin, A., Barouche, F. and Wolf, A.P. (1989) Dopamine Blockade and Clinical Response: Evidence for Two Biological Subgroups of Schizophrenia. Am. 1 Psychiat.,146, 905–908.Google Scholar

Copyright information

© Springer Science+Business Media New York 2001

Authors and Affiliations

  • Jan Libiger
    • 1
  1. 1.Psychiatric Center PraguePragueCzech Republic

Personalised recommendations